Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Semaglutide Pen Injector [Ozempic]
Semaglutide Pen Injector · 3 trials · 6 indications
mean severity grade (0-II)
Measured as VAT/Subcutaneous Adipose Tissue + VAT changes over 1 year.
Hepatic insulin resistance, measured by serum concentration of beta-hydroxybutyrate (surrogate marker of acetyl-CoA, which regulates gluconeogenesis), changes over 1 year.
Change in triglycerides after a high-fat mixed meal tolerance test, expressed as the total Area Under the Curve (AUCTG) over 6 hours from baseline to 1 year.
Weight measured in kilograms
| Arm | Type | Description |
|---|---|---|
| Semaglutide | ACTIVE_COMPARATOR | Semaglutide active drug 0.25-0.5mg, once-weekly, injection |
| Placebo | PLACEBO_COMPARATOR | Semaglutide placebo, once-weekly, injection |
| Name | Type | Description |
|---|---|---|
| Semaglutide Pen Injector [Ozempic] | DRUG | Semaglutide active drug |
| Placebo | DRUG | semaglutide placebo |
| Semaglutide Pen Injector | DRUG | Escalated to 2.4mg or max tolerated dose |
Inclusion Criteria: * Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma or follicular lymphoma * Age ≥ 18 years * BMI ≥ 18.5 * ECOG performance status\* ≤ 2 * Literate in Danish and/or English Exclusion Criteria: * Diabetes * Inflammatory bowel disease * Previous or current gastro...
Semaglutide Pen Injector is being studied for intestinal mucositis, type 1 diabetes, and nonalcoholic fatty liver disease (NAFLD). It is an investigational small molecule GLP-1 receptor agonist in Phase 2 clinical development for these metabolic and inflammatory conditions.
Semaglutide Pen Injector targets the glucagon-like peptide-1 receptor (GLP1R) and acts as an agonist. By activating GLP1R, it mimics the action of the natural GLP-1 hormone, which is involved in glucose metabolism and appetite regulation.
Semaglutide Pen Injector is developed by Novo Nordisk A/S, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting Phase 2 clinical trials to evaluate the drug for multiple indications.
Semaglutide Pen Injector is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The compound has received accelerated approval designation, indicating a potential pathway for expedited development.
Semaglutide Pen Injector is being evaluated in three Phase 2 trials: NCT05424003 for NAFLD, NCT06411210 for type 1 diabetes and obesity, and NCT06449625 for intestinal mucositis. All are randomized, double-blind, placebo-controlled studies with a combined enrollment of 144 participants.
Yes, Semaglutide Pen Injector is also known as Ozempic. The drug is being studied under the brand name Ozempic in clinical trials for conditions including NAFLD, type 1 diabetes, and intestinal mucositis.